Citigroup
BIOS

Citigroup’s BioPlus Acquisition Corp. Class A Ordinary Shares BIOS Stock Holding History

Citigroup’s Portfolio BIOS Stock Details BIOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-394,980
Closed -$3.96M – 6062
2022
Q3 		$3.96M Buy
394,980
+123,780
+46% +$1.24M ﹤0.01% 1681
2022
Q2 		$2.73M Hold
271,200
– – ﹤0.01% 1895
2022
Q1 		$2.68M Buy
+271,200
New +$2.68M ﹤0.01% 2118

Other funds holding BIOS

SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $7.02B AUM 31.58% 1-Year Est. Return
SV
Starboard Value New York $4.52B AUM 19.34% 1-Year Est. Return

Citigroup's BIOS Position: Q4 2022 in Review

Citigroup sold out of BioPlus Acquisition Corp. Class A Ordinary Shares (BIOS) in Q4 2022, closing a stake of 394,980 shares — an estimated $3.96M sold.

Citigroup first reported a position in BIOS in Q1 2022 and held it in 3 quarters. The position peaked at $3.96M in Q3 2022. 67 funds tracked by Wall St. Rank hold BIOS as of Q4 2022.

  • Citigroup reported no remaining BioPlus Acquisition Corp. Class A Ordinary Shares position as of Q4 2022 after selling out during the quarter.
  • Citigroup sold 394,980 BioPlus Acquisition Corp. Class A Ordinary Shares shares in Q4 2022, an estimated $3.96M.
  • Citigroup first reported a position in BioPlus Acquisition Corp. Class A Ordinary Shares in Q1 2022 and held it in 3 quarters.
  • Citigroup's BioPlus Acquisition Corp. Class A Ordinary Shares position peaked at $3.96M in Q3 2022.
  • 67 funds tracked by Wall St. Rank held BioPlus Acquisition Corp. Class A Ordinary Shares as of Q4 2022.

Based on Citigroup's 13F filing for Q4 2022, filed 9 Feb 2023.